Long-term Complete Response with Lapatinib Plus Capecitabine in a Patient with HER2-Positive Breast Cancer Metastasized to the Pancreas.
10.12771/emj.2015.38.3.138
- Author:
Kichul SHIN
1
;
Jinsu KIM
;
Seokyoung YOON
;
Eung Ho CHO
;
Changwon JUNG
;
Hye Jin KANG
Author Information
1. Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea. hyejin@kcch.re.kr
- Publication Type:Case Report
- Keywords:
Breast neoplasms;
Lapatinib;
Capecitabine;
Pancreas
- MeSH:
Adult;
Breast Neoplasms*;
Breast*;
Chemotherapy, Adjuvant;
Drug Therapy;
Female;
Humans;
Lung;
Mastectomy, Simple;
Neoplasm Metastasis;
Pancreas*;
Pancreaticoduodenectomy;
Radiotherapy, Image-Guided;
Tail;
Capecitabine;
Trastuzumab
- From:The Ewha Medical Journal
2015;38(3):138-143
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 37-year-old woman underwent a total mastectomy and adjuvant chemotherapy for HER2-positive breast cancer (pT1N0M), and then recurred in the right lung followed by the pancreas. Lung lobectomy and pylorus-preserving pancreaticoduodenectomy were performed, and systemic chemotherapies including trastuzumab were sequentially administered. However, metastasis to the pancreatic tail was detected. She underwent image-guided radiation therapy, but this was not effective. Lapatinib plus capecitabine combination was administered as forth-line treatment and the metastatic lesion was disappeared. She is continuing this regimen with a complete response for 48 months until now.
